| Nonbiopsy diagnosis of cardiac transthyretin amyloidosis JD Gillmore, MS Maurer, RH Falk, G Merlini, T Damy, A Dispenzieri, ... Circulation 133 (24), 2404-2412, 2016 | 1664 | 2016 |
| A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis AD Wechalekar, SO Schonland, E Kastritis, JD Gillmore, MA Dimopoulos, ... Blood, The Journal of the American Society of Hematology 121 (17), 3420-3427, 2013 | 494 | 2013 |
| A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis G Palladini, U Hegenbart, P Milani, C Kimmich, A Foli, AD Ho, MV Rosin, ... Blood, The Journal of the American Society of Hematology 124 (15), 2325-2332, 2014 | 453 | 2014 |
| A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis G Palladini, S Sachchithanantham, P Milani, J Gillmore, A Foli, ... Blood, The Journal of the American Society of Hematology 126 (5), 612-615, 2015 | 415 | 2015 |
| Management of AL amyloidosis in 2020 G Palladini, P Milani, G Merlini Blood, The Journal of the American Society of Hematology 136 (23), 2620-2627, 2020 | 243 | 2020 |
| The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best … G Palladini, A Barassi, C Klersy, R Pacciolla, P Milani, G Sarais, S Perlini, ... Blood, The Journal of the American Society of Hematology 116 (18), 3426-3430, 2010 | 239 | 2010 |
| A practical approach to the diagnosis of systemic amyloidoses C Fernández de Larrea, L Verga, P Morbini, C Klersy, F Lavatelli, A Foli, ... Blood, The Journal of the American Society of Hematology 125 (14), 2239-2244, 2015 | 204 | 2015 |
| Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach G Palladini, P Milani, A Foli, L Obici, F Lavatelli, M Nuvolone, ... haematologica 99 (4), 743, 2014 | 173 | 2014 |
| The lung in amyloidosis P Milani, M Basset, F Russo, A Foli, G Palladini, G Merlini European Respiratory Review 26 (145), 2017 | 160 | 2017 |
| Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure G Palladini, A Foli, P Milani, P Russo, R Albertini, F Lavatelli, L Obici, ... American journal of hematology 87 (5), 465-471, 2012 | 144 | 2012 |
| Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients G Palladini, P Milani, A Foli, M Vidus Rosin, M Basset, F Lavatelli, ... Leukemia 28 (12), 2311-2316, 2014 | 138 | 2014 |
| Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient P Swuec, F Lavatelli, M Tasaki, C Paissoni, P Rognoni, M Maritan, ... Nature communications 10 (1), 1269, 2019 | 135 | 2019 |
| Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis E Kastritis, X Leleu, B Arnulf, E Zamagni, MT Cibeira, F Kwok, P Mollee, ... Journal of Clinical Oncology 38 (28), 3252-3260, 2020 | 130 | 2020 |
| The utility of MASS‐FIX to detect and monitor monoclonal proteins in the clinic P Milani, DL Murray, DR Barnidge, MC Kohlhagen, JR Mills, G Merlini, ... American journal of hematology 92 (8), 772-779, 2017 | 116 | 2017 |
| Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome P Milani, M Basset, F Russo, A Foli, G Merlini, G Palladini Blood, The Journal of the American Society of Hematology 130 (5), 625-631, 2017 | 111 | 2017 |
| Light chain amyloidosis P Milani, G Merlini, G Palladini Mediterranean journal of hematology and infectious diseases 10 (1), 2018 | 109 | 2018 |
| Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide G Palladini, P Russo, A Foli, P Milani, F Lavatelli, L Obici, M Nuvolone, ... Annals of Hematology 91, 89-92, 2012 | 106 | 2012 |
| A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis G Palladini, P Milani, A Foli, M Basset, F Russo, S Perlini, G Merlini Blood, The Journal of the American Society of Hematology 129 (15), 2120-2123, 2017 | 101 | 2017 |
| The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity L Oliva, U Orfanelli, M Resnati, A Raimondi, A Orsi, E Milan, G Palladini, ... Blood, The Journal of the American Society of Hematology 129 (15), 2132-2142, 2017 | 86 | 2017 |
| A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis G Palladini, P Russo, P Milani, A Foli, F Lavatelli, M Nuvolone, S Perlini, ... Haematologica 98 (3), 433, 2013 | 81 | 2013 |
